Phase 2
Completed N=10
Extending Ketamine's Effects in OCD With Exposure and Response Prevention (EX/RP)
Source: ClinicalTrials.gov NCT02062658 ↗Enrolled (actual)
10
Serious AEs
0.0%
Results posted
Oct 2016
Primary outcomePrimary: Number of Patients Who Met and Exceeded Response Criteria of Yale-Brown Obsessive-Compulsive Scale — 5 participants
Summary
This study investigates if a single dose of IV Ketamine can rapidly improve Obsessive-Compulsive Disorder (OCD) symptoms and whether these effect can be maintained with a condensed course of a type of Cognitive Behavioral Therapy called Exposure and Response Prevention (EX/RP). You will be compensated for your time and travel. Participants must be between the ages of 18-55.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Patients Who Met and Exceeded Response Criteria of Yale-Brown Obsessive-Compulsive Scale |
5 | — |
Eligibility Criteria
Inclusion Criteria
- Age 18-55
- Physically healthy and not currently pregnant
- Primary Diagnosis of OCD
- Sufficient severity of symptoms
- Currently off all psychotropic medication OR
- Currently on adequate dose of medication for treatment of OCD, but have not achieved at least partial remission
- Able to provide consent
Exclusion Criteria
- Psychiatric conditions that make participation unsafe (schizophrenia [either self or first degree relative e.g. siblings, parents], history of violence, severe depression, eating disorder, substance dependence [including nicotine])
- Female patients who are either pregnant or nursing
- Planning to commence EX/RP during the period of the study or those who have completed an adequate dose of EX/RP (defined as 8 or more sessions within 2 months) within 8 weeks prior to enrollment.
period of the study
- Allergy to ketamine
- Participants for whom being off of medication is not clinically recommended
- Medical conditions that make participation unsafe (e.g. high blood pressure, head injury)
- Currently on medications that make participation unsafe
Data sourced from ClinicalTrials.gov (NCT02062658). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.